Aduro BioTech (ADRO) Given a $10.00 Price Target by HC Wainwright Analysts

Aduro BioTech (NASDAQ:ADRO) has been given a $10.00 price target by research analysts at HC Wainwright in a report issued on Tuesday. The firm currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price objective points to a potential upside of 23.46% from the stock’s previous close.

Several other analysts have also recently issued reports on ADRO. William Blair reiterated an “outperform” rating on shares of Aduro BioTech in a research note on Monday, October 2nd. Oppenheimer initiated coverage on shares of Aduro BioTech in a report on Monday, October 30th. They issued a “buy” rating and a $15.00 price target on the stock. BidaskClub lowered shares of Aduro BioTech from a “hold” rating to a “sell” rating in a report on Saturday, December 9th. Finally, Canaccord Genuity set a $30.00 price target on shares of Aduro BioTech and gave the stock a “buy” rating in a report on Thursday, December 14th. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $17.71.

Shares of Aduro BioTech (ADRO) opened at $8.10 on Tuesday. Aduro BioTech has a 52 week low of $6.01 and a 52 week high of $14.05.

Aduro BioTech (NASDAQ:ADRO) last posted its earnings results on Tuesday, October 31st. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.03). Aduro BioTech had a negative return on equity of 39.28% and a negative net margin of 548.92%. The firm had revenue of $3.79 million during the quarter, compared to analysts’ expectations of $4.04 million. During the same quarter in the prior year, the company earned ($0.54) earnings per share. The business’s revenue for the quarter was up .0% compared to the same quarter last year. analysts anticipate that Aduro BioTech will post -1.28 earnings per share for the current fiscal year.

In related news, COO Gregory W. Schafer sold 20,000 shares of the stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $10.75, for a total transaction of $215,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Dirk G. Brockstedt sold 65,223 shares of the stock in a transaction on Friday, December 15th. The shares were sold at an average price of $8.11, for a total transaction of $528,958.53. Following the transaction, the executive vice president now directly owns 137,826 shares in the company, valued at approximately $1,117,768.86. The disclosure for this sale can be found here. Insiders sold a total of 316,365 shares of company stock worth $2,858,183 in the last three months. Insiders own 6.60% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in ADRO. Legal & General Group Plc grew its holdings in shares of Aduro BioTech by 11.2% during the 2nd quarter. Legal & General Group Plc now owns 10,359 shares of the biotechnology company’s stock valued at $118,000 after purchasing an additional 1,043 shares during the last quarter. Fox Run Management L.L.C. bought a new position in shares of Aduro BioTech during the 3rd quarter valued at $127,000. SG Americas Securities LLC bought a new position in shares of Aduro BioTech during the 3rd quarter valued at $167,000. Trexquant Investment LP bought a new position in shares of Aduro BioTech during the 3rd quarter valued at $175,000. Finally, Voya Investment Management LLC grew its holdings in shares of Aduro BioTech by 15.3% during the 2nd quarter. Voya Investment Management LLC now owns 18,935 shares of the biotechnology company’s stock valued at $216,000 after purchasing an additional 2,515 shares during the last quarter. 45.19% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This story was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at https://sportsperspectives.com/2017/12/21/aduro-biotech-adro-given-a-10-00-price-target-by-hc-wainwright-analysts.html.

About Aduro BioTech

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Analyst Recommendations for Aduro BioTech (NASDAQ:ADRO)

Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply